Literature DB >> 26966191

MYC regulates the antitumor immune response through CD47 and PD-L1.

Stephanie C Casey1, Ling Tong1, Yulin Li1, Rachel Do1, Susanne Walz2, Kelly N Fitzgerald1, Arvin M Gouw1, Virginie Baylot1, Ines Gütgemann3, Martin Eilers4, Dean W Felsher5.   

Abstract

The MYC oncogene codes for a transcription factor that is overexpressed in many human cancers. Here we show that MYC regulates the expression of two immune checkpoint proteins on the tumor cell surface: the innate immune regulator CD47 (cluster of differentiation 47) and the adaptive immune checkpoint PD-L1 (programmed death-ligand 1). Suppression of MYC in mouse tumors and human tumor cells caused a reduction in the levels of CD47 and PD-L1 messenger RNA and protein. MYC was found to bind directly to the promoters of the Cd47 and Pd-l1 genes. MYC inactivation in mouse tumors down-regulated CD47 and PD-L1 expression and enhanced the antitumor immune response. In contrast, when MYC was inactivated in tumors with enforced expression of CD47 or PD-L1, the immune response was suppressed, and tumors continued to grow. Thus, MYC appears to initiate and maintain tumorigenesis, in part, through the modulation of immune regulatory molecules.
Copyright © 2016, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26966191      PMCID: PMC4940030          DOI: 10.1126/science.aac9935

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  45 in total

1.  Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia.

Authors:  Mark P Chao; Ash A Alizadeh; Chad Tang; Max Jan; Rachel Weissman-Tsukamoto; Feifei Zhao; Christopher Y Park; Irving L Weissman; Ravindra Majeti
Journal:  Cancer Res       Date:  2010-12-21       Impact factor: 12.701

2.  CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis.

Authors:  Siddhartha Jaiswal; Catriona H M Jamieson; Wendy W Pang; Christopher Y Park; Mark P Chao; Ravindra Majeti; David Traver; Nico van Rooijen; Irving L Weissman
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

3.  Transcriptional amplification in tumor cells with elevated c-Myc.

Authors:  Charles Y Lin; Jakob Lovén; Peter B Rahl; Ronald M Paranal; Christopher B Burge; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2012-09-28       Impact factor: 41.582

4.  Control of cell growth by c-Myc in the absence of cell division.

Authors:  M Schuhmacher; M S Staege; A Pajic; A Polack; U H Weidle; G W Bornkamm; D Eick; F Kohlhuber
Journal:  Curr Biol       Date:  1999-11-04       Impact factor: 10.834

Review 5.  Anti-PD-1 therapy in melanoma.

Authors:  Blanca Homet Moreno; Giulia Parisi; Lidia Robert; Antoni Ribas
Journal:  Semin Oncol       Date:  2015-02-13       Impact factor: 4.929

Review 6.  Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

Authors:  Padmanee Sharma; James P Allison
Journal:  Cell       Date:  2015-04-09       Impact factor: 41.582

Review 7.  Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Curr Opin Immunol       Date:  2012-01-09       Impact factor: 7.486

8.  Reversible tumorigenesis by MYC in hematopoietic lineages.

Authors:  D W Felsher; J M Bishop
Journal:  Mol Cell       Date:  1999-08       Impact factor: 17.970

Review 9.  Taming of the beast: shaping Myc-dependent amplification.

Authors:  Elmar Wolf; Charles Y Lin; Martin Eilers; David L Levens
Journal:  Trends Cell Biol       Date:  2014-12-01       Impact factor: 20.808

10.  c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations.

Authors:  C M D'Cruz; E J Gunther; R B Boxer; J L Hartman; L Sintasath; S E Moody; J D Cox; S I Ha; G K Belka; A Golant; R D Cardiff; L A Chodosh
Journal:  Nat Med       Date:  2001-02       Impact factor: 53.440

View more
  419 in total

Review 1.  How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy.

Authors:  Jinyang Li; Ben Z Stanger
Journal:  Cancer Res       Date:  2020-06-18       Impact factor: 12.701

2.  The Myc and Ras Partnership in Cancer: Indistinguishable Alliance or Contextual Relationship?

Authors:  Wadie D Mahauad-Fernandez; Dean W Felsher
Journal:  Cancer Res       Date:  2020-07-30       Impact factor: 12.701

3.  TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype.

Authors:  David A Sallman; Amy F McLemore; Amy L Aldrich; Rami S Komrokji; Kathy L McGraw; Abhishek Dhawan; Susan Geyer; Hsin-An Hou; Erika A Eksioglu; Amy Sullivan; Sarah Warren; Kyle J MacBeth; Manja Meggendorfer; Torsten Haferlach; Steffen Boettcher; Benjamin L Ebert; Najla H Al Ali; Jeffrey E Lancet; John L Cleveland; Eric Padron; Alan F List
Journal:  Blood       Date:  2020-12-10       Impact factor: 22.113

Review 4.  Mechanisms of Immune Tolerance in Leukemia and Lymphoma.

Authors:  Emily K Curran; James Godfrey; Justin Kline
Journal:  Trends Immunol       Date:  2017-05-13       Impact factor: 16.687

Review 5.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

Review 6.  Emerging roles of p53 and other tumour-suppressor genes in immune regulation.

Authors:  César Muñoz-Fontela; Anna Mandinova; Stuart A Aaronson; Sam W Lee
Journal:  Nat Rev Immunol       Date:  2016-09-26       Impact factor: 53.106

Review 7.  Cancer stem cells: Regulation programs, immunological properties and immunotherapy.

Authors:  Dingxiao Zhang; Dean G Tang; Kiera Rycaj
Journal:  Semin Cancer Biol       Date:  2018-05-09       Impact factor: 15.707

8.  Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation.

Authors:  Rebecca L Vartuli; Hengbo Zhou; Lingdi Zhang; Rani K Powers; Jared Klarquist; Pratyaydipta Rudra; Melanie Y Vincent; Debashis Ghosh; James C Costello; Ross M Kedl; Jill E Slansky; Rui Zhao; Heide L Ford
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

Review 9.  Optogenetic Immunomodulation: Shedding Light on Antitumor Immunity.

Authors:  Peng Tan; Lian He; Gang Han; Yubin Zhou
Journal:  Trends Biotechnol       Date:  2016-09-28       Impact factor: 19.536

10.  MiR-200c-3p Contrasts PD-L1 Induction by Combinatorial Therapies and Slows Proliferation of Epithelial Ovarian Cancer through Downregulation of β-Catenin and c-Myc.

Authors:  Eleni Anastasiadou; Elena Messina; Tiziana Sanavia; Lucia Mundo; Federica Farinella; Stefano Lazzi; Francesca Megiorni; Simona Ceccarelli; Paola Pontecorvi; Francesco Marampon; Cira Rosaria Tiziana Di Gioia; Giorgia Perniola; Pierluigi Benedetti Panici; Lorenzo Leoncini; Pankaj Trivedi; Andrea Lenzi; Cinzia Marchese
Journal:  Cells       Date:  2021-03-01       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.